<DOC>
	<DOCNO>NCT00420719</DOCNO>
	<brief_summary>The overall goal research delay respiratory decline patient Amyotrophic Lateral Sclerosis ( ALS ) thereby increase lifespan conditioning diaphragm laparoscopically place electrode . This device currently hold Investigational Device Exemption No . G040142 United States currently undergo clinical trial University Hospitals ( Cleveland ) , Johns Hopkins , Mayo Clinic Jacksonville , California Pacific Medical Center ( CPMC ) , Henry Ford Health System , The Methodist Hospital , Stanford University .</brief_summary>
	<brief_title>Motor-Point Stimulation Conditioning Diaphragm Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>The purpose study demonstrate safety efficacy NeuRX RA/4 Diaphragm Pacing Stimulation ( DPS ) System condition diaphragm ALS patient improve quality life slow progression respiratory failure . Amyotrophic Lateral Sclerosis ( ALS , also know Lou Gehrig 's disease Motor Neuron Disease ) progressive neurodegenerative disease unknown cause . One important effect progressive neuromuscular weakness patient ALS effect respiration . Although ALS direct effect lung , devastate effect mechanical function respiratory system . ALS affect major respiratory muscle group : upper airway muscle , expiratory muscle , inspiratory muscle . Therefore , patient ALS significant risk respiratory complication . Progressive inspiratory muscle weakness ALS inevitably lead carbon dioxide retention , inability clear secretion hypercarbic respiratory failure , major cause death ALS . Synapse Biomedical , conjunction Case Western Reserve University University Hospitals Cleveland , evaluate activate diaphragm percutaneous intramuscular electrode implant laparoscopically . This eliminate direct contact phrenic nerve , allow circuitry electronics remain outside body , provide direct , selective activation hemidiaphragm . The NeuRx-RA/4 DPS System provide electrical signal motor point muscle cause diaphragm contract allow patient breathe naturally . The NeuRx RA/4 DPS System implant 10 individual ALS , pilot study University Hospitals Cleveland begin January , 2005 . The NeuRx RA/4 DPS System platform , also use respiratory support individual high-level spinal cord injury , 56 year cumulative active implantation time . The long term patient implant March 6 , 2000 use DPS System sole mean respiratory support six year . Given patient result date data support safety efficacy proceed pivotal study patient population . With unexpected significant adverse event report , NeuRx RA/4 DPS System perform reliably safely . Device Description : The NeuRx RA/4 Respiratory System manufacture Synapse Biomedical . The NeuRx RA/4 System comprise follow component : external , battery power Stimulator Device , associate Programmer/Controller , Intramuscular Electrodes , associate percutaneous Lead Wires , Surgical Placement Tool Set , surgical Mapping Station . Inclusion Criteria : - Age 18 old - Participants familial sporadic ALS diagnose laboratory-supported probable , probable , definite accord World Federation Neurology El Escorial criterion eligible - Bilateral phrenic nerve function clinically acceptable demonstrated bilateral diaphragm movement fluoroscopic sniff test EMG recording nerve conduction time - Forced Vital Capacity ( FVC ) 50 - 85 % predicted value begin screen procedure . - FVC great 45 % predict value time surgery . - No underlying cardiac pulmonary disease would increase risk general anesthesia great expect risk patient ALS - Negative pregnancy test females child-bearing potential - Informed consent patient designate representative Exclusion Criteria : - Preexisting implanted electrical device pacemaker cardiac defibrillator . - Underlying pulmonary disease present prior ALS would effect pulmonary test independent ALS . - Active cardiovascular disease would increase risk general anesthesia - Current pregnancy breastfeed - Hospitalization treat active infection within last 2 month - Significant decision make incapacity preventing informed consent subject due major mental disorder major depression schizophrenia , dementia Alzheimer 's disease . - Marked obesity</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Age 18 old Participants familial sporadic ALS diagnose laboratorysupported probable , probable , definite accord World Federation Neurology El Escorial criterion eligible Bilateral phrenic nerve function clinically acceptable demonstrated bilateral diaphragm movement fluoroscopic sniff test EMG recording nerve conduction time Forced Vital Capacity ( FVC ) 50 85 % predicted value begin screen procedure . FVC great 45 % predict value time surgery . No underlying cardiac pulmonary disease would increase risk general anesthesia great expect risk patient ALS Negative pregnancy test female childbearing potential Informed consent patient designate representative Preexisting implant electrical device pacemaker cardiac defibrillator . Underlying pulmonary disease present prior ALS would effect pulmonary test independent ALS Active cardiovascular disease would increase risk general anesthesia Current pregnancy breastfeed Hospitalization treat active infection within last 2 month Significant decision make incapacity preventing informed consent subject due major mental disorder major depression schizophrenia , dementia Alzheimer 's disease . Marked obesity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>ALS</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
	<keyword>Diaphragm Ventilatory Assist</keyword>
	<keyword>Diaphragm Pacing</keyword>
</DOC>